Details

Autor(en) / Beteiligte

• Zhao, Wen-Ning
• Tobe, Brian T D
• Udeshi, Namrata D
• Xuan, Lucius L
• Pernia, Cameron D
• Zolg, Daniel P
• Roberts, Amanda J
• Mani, Deepak
• Blumenthal, Sarah R
• Kurtser, Iren
• Patnaik, Debasis
• Gaisina, Irina
• Bishop, Joshua
• Sheridan, Steven D
• Lalonde, Jasmin
• Carr, Steven A
• Snyder, Evan Y
• Haggarty, Stephen J

Titel

Discovery of suppressors of CRMP2 phosphorylation reveals compounds that mimic the behavioral effects of lithium on amphetamine-induced hyperlocomotion

Ist Teil von

• Translational psychiatry, 2020-02, Vol.10 (1), p.76-76, Article 76

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2020

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• The effective treatment of bipolar disorder (BD) represents a significant unmet medical need. Although lithium remains a mainstay of treatment for BD, limited knowledge regarding how it modulates affective behavior has proven an obstacle to discovering more effective mood stabilizers with fewer adverse side effects. One potential mechanism of action of lithium is through inhibition of the serine/threonine protein kinase GSK3β, however, relevant substrates whose change in phosphorylation may mediate downstream changes in neuroplasticity remain poorly understood. Here, we used human induced pluripotent stem cell (hiPSC)-derived neuronal cells and stable isotope labeling by amino acids in cell culture (SILAC) along with quantitative mass spectrometry to identify global changes in the phosphoproteome upon inhibition of GSK3α/β with the highly selective, ATP-competitive inhibitor CHIR-99021. Comparison of phosphorylation changes to those induced by therapeutically relevant doses of lithium treatment led to the identification of collapsin response mediator protein 2 (CRMP2) as being highly sensitive to both treatments as well as an extended panel of structurally distinct GSK3α/β inhibitors. On this basis, a high-content image-based assay in hiPSC-derived neurons was developed to screen diverse compounds, including FDA-approved drugs, for their ability to mimic lithium's suppression of CRMP2 phosphorylation without directly inhibiting GSK3β kinase activity. Systemic administration of a subset of these CRMP2-phosphorylation suppressors were found to mimic lithium's attenuation of amphetamine-induced hyperlocomotion in mice. Taken together, these studies not only provide insights into the neural substrates regulated by lithium, but also provide novel human neuronal assays for supporting the development of mechanism-based therapeutics for BD and related neuropsychiatric disorders.